The effect of light exposure on insomnia and nocturnal movement in Parkinson's disease: an open label, retrospective, longitudinal study

Martino, Jessica K.; Freelance, Christopher B.; Willis, Gregory L.

doi:10.1016/j.sleep.2018.01.001

Cited by 43 publications

(30 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, novel therapies using light stimulation to synchronize circadian rhythms are demonstrating beneficial results in PD [ 24 , 29 , 36 ]. Martino et al found that long-term light therapy improves sleep quality, reduces awakenings during the night and increases the total sleep time [ 42 ]. Light therapy was also found to be effective for excessive daytime sleepiness and global sleep quality [ 53 ].…”

Section: Discussionmentioning

confidence: 99%

Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s disease

Ortuño‐Lizarán

Esquiva

Beach

et al. 2018

acta neuropathol commun

View full text Add to dashboard Cite

Parkinson’s disease (PD) patients often suffer from non-motor symptoms like sleep dysregulation, mood disturbances or circadian rhythms dysfunction. The melanopsin-containing retinal ganglion cells are involved in the control and regulation of these processes and may be affected in PD, as other retinal and visual implications have been described in the disease. Number and morphology of human melanopsin-containing retinal ganglion cells were evaluated by immunohistochemistry in eyes from donors with PD or control. The Sholl number of intersections, the number of branches, and the number of terminals from the Sholl analysis were significantly reduced in PD melanopsin ganglion cells. Also, the density of these cells significantly decreased in PD compared to controls. Degeneration and impairment of the retinal melanopsin system may affect to sleep and circadian dysfunction reported in PD pathology, and its protection or stimulation may lead to better disease prospect and global quality of life of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s disease

Ortuño‐Lizarán

Esquiva

Beach

et al. 2018

acta neuropathol commun

View full text Add to dashboard Cite

show abstract

“…Light therapy (LT) has expanded in application to other neuropsychiatric domains—some examples are to be found in studies of bipolar disorder (Benedetti, ), borderline personality disorder (Bromundt et al., ), Parkinson's disease (Martino, Freelance, & Willis, ; Videnovic et al., ), fibromyalgia (Burgess et al., )—and even to internal medicine, for example, insomnia in cirrhosis (De Rui et al., ) or post‐kidney transplantation (Burkhalter et al., ), depression in cystic fibrosis patients (Kopp et al., ), post‐stroke (Sondergaard, Jarden, Martiny, Andersen, & Bech, ) and cancer (Dallaspezia, Cantamessa, & Benedetti, ). Light probably does not treat the illness per se , but it can aid in reducing concomitant symptoms of poor sleep and daytime alertness.…”

Section: Where Are We Today?mentioning

confidence: 99%

Perspectives in affective disorders: Clocks and sleep

Wirz‐Justice

Benedetti

2019

Eur J of Neuroscience

View full text Add to dashboard Cite

Mood disorders are often characterised by alterations in circadian rhythms, sleep disturbances and seasonal exacerbation. Conversely, chronobiological treatments utilise zeitgebers for circadian rhythms such as light to improve mood and stabilise sleep, and manipulations of sleep timing and duration as rapid antidepressant modalities. Although sleep deprivation (“wake therapy”) can act within hours, and its mood‐elevating effects be maintained by regular morning light administration/medication/earlier sleep, it has not entered the regular guidelines for treating affective disorders as a first‐line treatment. The hindrances to using chronotherapeutics may lie in their lack of patentability, few sponsors to carry out large multi‐centre trials, non‐reimbursement by medical insurance and their perceived difficulty or exotic “alternative” nature. Future use can be promoted by new technology (single‐sample phase measurements, phone apps, movement and sleep trackers) that provides ambulatory documentation over long periods and feedback to therapist and patient. Light combinations with cognitive behavioural therapy and sleep hygiene practice may speed up and also maintain response. The urgent need for new antidepressants should hopefully lead to reconsideration and implementation of these non‐pharmacological methods, as well as further clinical trials. We review the putative neurochemical mechanisms underlying the antidepressant effect of sleep deprivation and light therapy, and current knowledge linking clocks and sleep with affective disorders: neurotransmitter switching, stress and cortico‐limbic reactivity, clock genes, cortical neuroplasticity, connectomics and neuroinflammation. Despite the complexity of multi‐system mechanisms, more insight will lead to fine tuning and better application of circadian and sleep‐related treatments of depression.

show abstract

“…Supporting this, a recent randomized clinical trial conducted a detailed evaluation of BLT-induced sleep improvement and found that BLT was significantly associated with improvements in excessive daytime sleepiness, sleep fragmentation and sleep quality 16 . The efficacy of BLT against sleep problems in DT-receiving PD patients was confirmed in an open-label, retrospective and longitudinal study 17 . In addition, another controlled exploratory trial shows that strategic application of polychromatic light to DT-receiving PD patients improved motor and non-motor symptoms including sleep problems 18 .…”

mentioning

confidence: 77%

Bright light improves sleep in patients with Parkinson’s disease: possible role of circadian restoration

Endo

Matsumura

Tokuda

et al. 2020

Sci Rep

View full text Add to dashboard Cite

parkinson's disease (pD) is one of the most common neurodegenerative disorders. Among the most common manifestations of PD are sleep problems, which are coupled with the adverse effects of dopaminergic therapies (Dt). A non-pharmacological solution for these sleep problems has been sought to avoid additional pharmacological intervention. Here, we show that bright light therapy (BLT) is effective for improving sleep in Japanese PD patients receiving DT. Furthermore, experimental evaluation of peripheral clock gene expression rhythms revealed that most PD patients receiving DT who experienced improved sleep following BLT showed a circadian phase shift, indicating the existence of a correlation between circadian modulation and sleep improvement. conversely, this result indicates that sleep problems in pD patients receiving Dt may arise at least in part as a result of circadian dysfunction. indeed, we found that chronic dopaminergic stimulation induced a rapid attenuation of autonomous oscillations of clock gene expression in ex vivo cultured mouse suprachiasmatic nucleus (Scn) at the single neuron level. in conclusion, BLt is a promising medical treatment for improving sleep in pD patients receiving Dt. this BLt-induced improvement may be due to the restoration of circadian function. Parkinson's disease is one of the most common neurodegenerative disorders, affecting approximately 10 million people worldwide 1. First-line treatment strategies involve implementation of dopaminergic therapies such as dopamine replacement therapy using levodopa which is converted to dopamine by enzymes in the brain 2,3. Among the most common manifestations of PD are sleep problems, which reduce quality of life and impair daytime functioning. For example, in a large survey of non-motor symptoms, 64% of PD patients reported sleep problems, representing the second most common non-motor complaint 4. Previous studies have suggested that PD symptoms and the adverse effects of medications may be some of the causes of sleep problems in PD patients 5-7. Because of the risk of interference with treatment regimens, few treatment options for sleep problems in PD are available; in particular, chronic sleep problems are coupled with the adverse effects of the medications prescribed for PD. Therefore, preventing sleep problems in patients with PD requires the development of non-pharmacological approaches. Several lines of evidence suggest that one cause of sleep problems in patients with PD is circadian dysfunction. First, dopaminergic therapy (DT)-receiving PD patients show a circadian phase advance and decrease in nighttime levels of melatonin 8,9. Melatonin is a pineal hormone whose circadian secretion is regulated by the hypothalamic SCN, the center of the circadian clock, via a polysynaptic efferent pathway 10. Concurrently, melatonin is thought to play a role in enhancing the robustness of suprachiasmatic circadian function by activating

show abstract

The effect of light exposure on insomnia and nocturnal movement in Parkinson's disease: an open label, retrospective, longitudinal study

Cited by 43 publications

References 58 publications

Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s disease

Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s disease

Perspectives in affective disorders: Clocks and sleep

Bright light improves sleep in patients with Parkinson’s disease: possible role of circadian restoration

Contact Info

Product

Resources

About